{
    "clinical_study": {
        "@rank": "61889", 
        "arm_group": [
            {
                "arm_group_label": "Experimental Arm B", 
                "arm_group_type": "Experimental", 
                "description": "48 weeks of peginterferon alfa-2b and ribavirin Plus Boceprevir 800 mg"
            }, 
            {
                "arm_group_label": "Control Arm", 
                "arm_group_type": "Active Comparator", 
                "description": "48 weeks of peginterferon alfa-2b and ribavirin"
            }
        ], 
        "brief_summary": {
            "textblock": "Hypothesis Combination of Boceprevir with Ribavirin in treatment-na\u00efve patients with\n      genotype 4 chronic hepatitis C infection will increase the proportion of patients achieving\n      sustained viral response compared to standard treatment alone."
        }, 
        "brief_title": "Study of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Genotype 4 Chronic Hepatitis C Infection", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives:\n\n      The primary objective of this study is to assess the efficacy and safety of Boceprevir 800\n      mg three times per day (TID) orally (PO) (hereafter called Boceprevir) in combination with\n      peginterferon alfa-2b 1.5 \u03bcg/kg once per week (QW) subcutaneously (SC) plus weight-based\n      dosing (WBD) of ribavirin (800 to 1400 mg/day) compared to standard of care (SOC) (therapy\n      with peginterferon alfa-2b (PEG)+ribavirin (RBV) WBD) in previously untreated adult subjects\n      with chronic hepatitis C (CHC) genotype 4 infection.\n\n      Primary Trial Objectives:\n\n      - The primary efficacy objective of this study is to assess the efficacy of Boceprevir in\n      combination with PEG 1.5 \u03bcg/kg QW SC plus WBD of RBV (800 to 1400 mg/day) compared to the\n      efficacy of SOC (therapy with PEG+RBV WBD) in the Control Arm in previously untreated adult\n      subjects with CHC genotype 4 infection"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Ages Eligible for Study: 18 Years and older\n\n          -  Genders Eligible for Study: Both\n\n        Inclusion Criteria:\n\n          -  Subject must be more than 18 years of age.\n\n          -  Subject's weight must be more than 40 kg and  less than 125 kg.\n\n          -  Subject and subject's partner must each agree to use acceptable methods of\n             contraception for at least 2 weeks prior to Day 1 and continue until at least 6\n             months after last dose of study medication, or longer if dictated by local\n             regulations.\n\n          -  Subjects must be willing to give written informed consent for the trial and for the\n             pharmacogenetic testing.\n\n          -  Subjects who are unwilling to provide written informed consent for pharmacogenetic\n             testing may be included in the trial; however, pharmacogenetic samples must not be\n             obtained.\n\n          -  Subject must have previously documented CHC genotype 4 infection.\n\n          -  Subjects with other or mixed genotypes are not eligible. The HCV-RNA result obtained\n             from the central laboratory at the screening visit must confirm genotype 4 infection\n             and be more10,000 IU per mL Previously untreated patients with Pegylated interferon\n\n          -  Subject must have a liver biopsy or fibrotest and fibroscan with histology consistent\n             with CHC and no other etiology.\n\n        Exclusion Criteria:\n\n          -  Subject who is coinfected with the human immunodeficiency virus (HIV) or hepatitis B\n             virus.\n\n          -  Prior treatment with interferon, ribavirin and/or investigational agent for hepatitis\n             C.\n\n          -  Prior treatments with herbal remedies with known hepatotoxicity are exclusionary.\n\n          -  All herbal remedies used for hepatitis C treatment must be discontinued before Day 1.\n\n          -  Treatment with any investigational drug within 30 days of the screening visit in this\n             trial.\n\n          -  Subject who received any of the following medication(s) within 2 weeks prior to the\n             Day 1 visit that are highly dependent on CYP3A4.5 for clearance, and for which\n             elevated plasma concentrations are associated with serious and or life-threatening\n             events such as: orally administered midazolam, pimozide, amiodarone, flecainide,\n             propafenone, quinidine and ergot derivatives (dihydroergotamine, ergonovine,\n             ergotamine, methylergonovine).\n\n          -  Evidence of decompensated liver disease including, but not limited to, a history or\n             presence of clinical ascites, bleeding varices, or hepatic encephalopathy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653236", 
            "org_study_id": "3034-108"
        }, 
        "intervention": [
            {
                "arm_group_label": "Experimental Arm B", 
                "intervention_name": "Boceprevir", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Experimental Arm B", 
                    "Control Arm"
                ], 
                "intervention_name": "Peginterferon alfa-2b", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Experimental Arm B", 
                    "Control Arm"
                ], 
                "intervention_name": "ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Ribavirin", 
                "Peginterferon alfa-2b", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 30, 2012", 
        "location": {
            "contact": {
                "email": "ibrahimmostafa@egyptgastrohep.com", 
                "last_name": "Ibrahim Mostafa, PHD", 
                "phone": "00201222113466"
            }, 
            "facility": {
                "address": {
                    "city": "Giza", 
                    "country": "Egypt", 
                    "zip": "12311"
                }, 
                "name": "Theodor Bilharz Research Institute"
            }, 
            "investigator": {
                "last_name": "Ibrahim Mostafa, PHD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "2", 
        "official_title": "Pilot Study to Determine the Efficacy and Safety of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Egypt: Ministry of Health (MOH)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy objective of this study is to assess the efficacy of Boceprevir in combination with PEG 1.5 \u03bcg/kg QW SC plus WBD of RBV (800 to 1400 mg/day) compared to the efficacy of SOC (therapy with PEG+RBV WBD) in the Control Arm in previously untreated adult subjects with CHC genotype 4 infection", 
            "measure": "Efficacy", 
            "safety_issue": "Yes", 
            "time_frame": "72 Weeks"
        }, 
        "reference": {
            "PMID": "21449783", 
            "citation": "Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar 31;364(13):1195-206. doi: 10.1056/NEJMoa1010494."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653236"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Theodor Bilharz Research Institute", 
            "investigator_full_name": "Ibrahim Mostafa", 
            "investigator_title": "Vice President", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "1. Assess the number of patients who achieved SVR after achieving undetectable or \u22652 log reduction of HCV RNA level at treatment week 8;", 
                "measure": "Week 8 Response", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "description": "Assess the number of patients who achieved SVR after achieving undetectable or \u22652 log reduction of HCV RNA level at treatment week 12", 
                "measure": "12 Weeks response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks"
            }, 
            {
                "description": "To evaluate the effect of IL-28B polymorphism (CC,CT,TT) alleles on the viral kinetic response after the addition of Boceprevir", 
                "measure": "IL-28B polymorphism", 
                "safety_issue": "No", 
                "time_frame": "72 Weeks"
            }
        ], 
        "source": "Theodor Bilharz Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theodor Bilharz Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2012"
    }
}